Finvest
ALMS Biotechnology · Clinical stage · Immunology · Pre-revenue · Thesis updated July 14, 2026

Envu now carries the Alumis story

01 Running thesis

One drug leads the case

The bull case is simple. Envu is Alumis's lead TYK2 inhibitor, a drug meant to calm immune signaling in a more targeted way than broad immune-suppressing drugs. Positive topline Phase 3 ONWARD results in plaque psoriasis moved the story from trial readout risk toward filing and launch risk.

The next major catalyst is the planned New Drug Application, or NDA, for envu in plaque psoriasis in the second half of 2026. If the FDA accepts the filing and later approves the drug, Alumis can start moving from a research company toward a commercial one.

The bear case is also clear. Alumis is still pre-revenue, burns cash to run trials, and depends heavily on envu. The ACELYRIN merger added work, costs, and assets to sort through at the same time Alumis needs to stay focused on envu's filing.

Pipeline diversification also looks weaker than it did right after the merger. Alumis completed a review of lonigutamab in May 2026 and chose to explore strategic alternatives for that program. That puts more pressure back on envu and the upcoming SLE Phase 2 data.

May 2026Alumis completed its review of lonigutamab and decided to explore strategic alternatives for the program. That weakens the diversification case and puts more weight back on envu.
Mar 2026Alumis reported positive topline Phase 3 ONWARD results for envu in plaque psoriasis. The main catalyst shifted from data readout risk to the planned NDA submission in the second half of 2026.
Nov 2025The Q3 2025 filing confirmed the existing setup. Envu Phase 3 data was still expected early in Q1 2026, and ACELYRIN integration costs remained a watch item.
Aug 2025The ACELYRIN merger closed, moving the risk from deal completion to integration. Alumis also formally added lonigutamab and renamed ESK-001 to envu.
May 2025The Q1 2025 filing did not change the clinical story. Cash, cash equivalents, and marketable securities were $208.7 million as of March 31, 2025.
Apr 2025The 10-K amendment mainly covered governance and compensation items. It did not change the business model, pipeline, or main risks.
Mar 2025Alumis disclosed the proposed ACELYRIN merger, which could broaden the immunology pipeline but also added deal and integration risk. Cash, cash equivalents, and marketable securities were $288.3 million at year-end 2024.
Nov 2024The July 2024 IPO and concurrent private placement brought in $233.3 million of net proceeds. Alumis reported $361.9 million of cash, cash equivalents, and marketable securities as of September 30, 2024.
02 Business model

Research first, sales later

Alumis does not sell approved drugs today. It spends investor capital on clinical trials, regulatory work, and drug development, with the goal of winning approvals and later earning revenue from drug sales or partnerships.

The company focuses on targeted immunology. That means it is trying to treat immune diseases by blocking specific signals, rather than using broad drugs that suppress large parts of the immune system.

Alumis does not own manufacturing plants. It relies on contract manufacturing organizations, called CMOs, to make clinical drug supply. That keeps fixed costs lower, but it adds dependence on outside partners for quality, timing, and scale.

The model breaks if envu is delayed, rejected, or cannot compete after approval. Before revenue arrives, Alumis must also keep funding trials and integration costs without letting dilution or cash pressure take over the story.

03 Product portfolio

Pipeline built around TYK2

Growth engine

Envudeucitinib, or envu, in plaque psoriasis

This is the lead asset. It completed pivotal Phase 3 ONWARD1 and ONWARD2 trials, reported positive topline results in Q1 2026, and is planned for an NDA submission in the second half of 2026.

Option

Envudeucitinib, or envu, in systemic lupus erythematosus

This is a Phase 2 use case for the same drug in lupus, an immune disease that can affect many organs. The expected Q3 2026 data could widen envu's value if it supports further study.

Option

A-005

A-005 is an investigational CNS-penetrant TYK2 molecule, meaning it is designed to reach the central nervous system. It is earlier stage and remains a longer-term pipeline option.

Option

Lonigutamab

Lonigutamab came from the ACELYRIN merger and targets IGF-1R for thyroid eye disease. Alumis completed a strategic review in May 2026 and is exploring strategic alternatives for the program.

04 Business segments

One reported segment

Research and development operating segment100%flat
Commercial products0%flat

Alumis reports one unified research and development operating segment and has generated no commercial revenue to date. The split below reflects that current business reality, with no product sales segment yet.

05 Risk factors

What could break it

Envu approval fails

High impact · Medium odds

Envu is the main value driver. If the FDA rejects the planned plaque psoriasis NDA, asks for another major trial, or raises a safety issue, Alumis would lose its clearest path to first revenue.

We watchThe planned envu NDA submission in the second half of 2026, FDA acceptance status, and any complete response letter.

Launch prep falls behind

High impact · Medium odds

Positive Phase 3 data does not by itself create a business. Alumis still needs regulatory execution, manufacturing supply, market access planning, and a commercial setup if envu is approved.

We watchUpdates on NDA timing, CMO readiness, hiring, and any changes to planned commercialization spending.

ACELYRIN integration drains focus

Medium impact · Medium odds

The ACELYRIN merger brought added assets and integration costs. Those costs could distract management or consume capital while envu needs careful filing and launch preparation.

We watchQuarterly operating expense trends and management comments on ACELYRIN integration costs.

Pipeline breadth shrinks

Medium impact · High odds

Lonigutamab was supposed to help diversify the pipeline after the merger. Alumis has now decided to explore strategic alternatives for the program, which means it may not remain a core asset.

We watchThe final outcome of the lonigutamab strategic alternatives process.

Earlier trials disappoint

Medium impact · Medium odds

Clinical failure risk is not theoretical. Alumis discontinued a Phase 2a envu trial in non-infectious uveitis in June 2024 after the efficacy results did not meet its threshold for success.

We watchThe expected Q3 2026 Phase 2 SLE data and any trial discontinuations or protocol changes.
06 Quick answers

In one breath

Does Alumis have revenue?

No. Alumis is a clinical-stage biotech and has generated no commercial revenue to date. Its value depends on whether its drugs can win approval and later sell in the market.

What is envu?

Envudeucitinib, or envu, is Alumis's lead TYK2 inhibitor. It is being developed first for plaque psoriasis, where Alumis reported positive topline Phase 3 ONWARD results in Q1 2026.

What is the next big Alumis catalyst?

The next major company event is the planned envu NDA submission for plaque psoriasis in the second half of 2026. Investors are also watching Phase 2 SLE data expected in Q3 2026 and the outcome of the lonigutamab review.